Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Rev. gastroenterol. Perú ; 38(4): 325-330, oct.-dic. 2018. ilus, tab
Artigo em Espanhol | LILACS | ID: biblio-1014104

RESUMO

Introducción: Una condición de alta mortalidad a corto plazo en el cirrótico es la Insuficiencia hepática crónica reagudizada (ACLF por sus siglas en inglés), caracterizada por la falla de órgano(s) y precedida habitualmente por una descompensación aguda (DA). Objetivo: Determinar la frecuencia, el perfil clínico y la mortalidad en los cirróticos hospitalizados con ACLF. Materiales y métodos: Estudio analítico observacional realizado de julio 2016 a junio 2017. Se estableció la condición de ACLF según los criterios del estudio CANONIC. Resultados: Se reclutaron 118 pacientes cirróticos, 34 (28,8%) de los cuales presentaron ACLF, con grado 1: 14 (41%), grado 2: 16 (47%) y grado 3: 4 (12%) pacientes. La edad promedio fue 61,5 años; siendo la etiología más frecuente el alcoholismo en 18 pacientes (53%) y la mayoría no tenían historia previa de DA (64,7%). Los factores precipitantes más frecuentes fueron: la hemorragia digestiva (41%) y las infecciones (29,4%). Los grupos con y sin ACLF tuvieron una diferencia estadísticamente significativa en el puntaje Child-Turcotte-Pugh (CTP) (11,4 ± 1,8 vs 8,69 ± 2,04; p<0,0001), puntaje MELD (26,4 ± 8,1 vs 14,4 ± 4,6; p<0,0001), leucocitos (11 809,7 ± 6906,3/mm3 vs 8434,01 ± 5434,9/mm3; p: 0,006) y mortalidad a 28 días (76,5% vs 21,4%; p<0,0001), con un riesgo relativo (RR) de 3,5. Conclusiones: La frecuencia de ACLF fue 28,8%, similar a la del estudio CANONIC (30,9%). El principal factor precipitante fue la hemorragia digestiva. Los puntajes CTP, MELD y leucocitos fueron más altos en el grupo con ACLF, observándose una mortalidad a 28 días de 76,5% (3,5 veces mayor que en los pacientes sin ACLF).


Introduction: A condition of high short-term mortality in the cirrhotic patient is Acute-on-Chronic Liver Failure (ACLF), characterized by organ failure (s) and usually preceded by acute decompensation (AD). Objective: To determine the frequency, clinical profile, and mortality in cirrhotic patients hospitalized with ACLF. Materials and methods: This is an observational analytical study conducted from July 2016 to June 2017. We established the ACLF condition through the criteria of the CANONIC study. Results: The study population was 118 patients, of whom 34 (28.8%) presented ACLF, 14 (41%) were Grade 1, 16 (47%) Grade 2 and 4 (11.9%) Grade 3. The average age was 61.5 years old, alcoholism being the most frequent etiology with 18 patients (53%) and mostly without episodes of AD (64.7%). The most frequent precipitating factors were: Digestive hemorrhage (41%) and infections (29.4%). The groups with and without ACLF were statistically significant in the Child-Turcot- Pugh score (CTP) (11.4 ± 1.8 vs. 8.69 ± 2.04; p < 0.0001), MELD score (26.4 ± 8.1 vs. 14.4 ± 4.6; p < 0.0001), leukocytes (11,809.7 +/- 6,906.3 per mm3 vs. 8,434.01 ± 5,434.9 per mm3; p: 0.006) and 28-day mortality (76.5% vs. 21.4%, p < 0.0001), with a relative risk (RR) of 3.5. Conclusions: The frecuency of ACLF was 28.8%, similar to that of the CANONIC study (30.9%). The digestive hemorrhage being the main precipitating factor. The CTP, MELD and leukocyte scores were highest in this group. Mortality in patients with ACLF was 3.5 times more frequent than in patients without ACLF.


Assuntos
Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Insuficiência Hepática Crônica Agudizada/diagnóstico , Insuficiência Hepática Crônica Agudizada/epidemiologia , Peru , Saúde da População Urbana , Estudos Prospectivos , Insuficiência Hepática Crônica Agudizada/etiologia , Insuficiência Hepática Crônica Agudizada/mortalidade , Hospitais Públicos , Cirrose Hepática/complicações
2.
Clinics ; 72(11): 686-692, Nov. 2017. tab, graf
Artigo em Inglês | LILACS | ID: biblio-890692

RESUMO

OBJECTIVE: To investigate the impact of the baseline status of patients with hepatitis B virus-associated acute-on-chronic liver failure on short-term outcomes. METHODS: A retrospective study was conducted that included a total of 138 patients with hepatitis B virus-associated acute-on-chronic liver failure admitted to the Department of Infectious Diseases, Taihe Hospital, Hubei University of Medicine, from November 2013 to October 2016. The patients were divided into a poor prognosis group (74 patients) and a good prognosis group (64 patients) based on the disease outcome. General information, clinical indicators and prognostic scores of the patients' baseline status were analyzed, and a prediction model was established accordingly. RESULTS: Elder age, treatment with artificial liver support systems and the frequency of such treatments, high levels of white blood cells, neutrophils, neutrophil count/lymphocyte count ratio, alanine aminotransferase, gamma-glutamyl transferase, total bilirubin, urea, and prognostic scores as well as low levels of albumin and sodium were all significantly associated with the short-term outcomes of hepatitis B virus-associated acute-on-chronic liver failure. The predictive model showed that logit (p) = 3.068 + 1.003 × neutrophil count/lymphocyte count ratio - 0.892 × gamma-glutamyl transferase - 1.138 × albumin - 1.364 × sodium + 1.651 × artificial liver support therapy. CONCLUSION: The neutrophil count/lymphocyte count ratio and serum levels of gamma-glutamyl transferase, albumin and sodium were independent risk factors predicting short-term outcomes of hepatitis B virus-associated acute-on-chronic liver failure, and the administration of multiple treatments with artificial liver support therapy during the early stage is conducive to improved short-term outcomes.


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Insuficiência Hepática Crônica Agudizada/virologia , Hepatite B/complicações , Prognóstico , Valor Preditivo dos Testes , Estudos Retrospectivos , Fatores de Risco , Sensibilidade e Especificidade , Insuficiência Hepática Crônica Agudizada/mortalidade , Insuficiência Hepática Crônica Agudizada/sangue , Insuficiência Hepática Crônica Agudizada/terapia , Hepatite B/mortalidade , Hepatite B/sangue , Hepatite B/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA